clinical trial · NCT06590961
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Ubix Therapeutics, Inc.·phase1·recruiting·n = 94
Relapsed/Refractory B-cell MalignanciesUBX-303061
brief summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
started
Feb 20, 2025
primary completion
Aug 1, 2027
completion
Aug 1, 2027
last updated
Nov 19, 2025
official title
A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol